SpindxTM is a portable point-of-care diagnostic platform capable of performing up to 64 assays from a single sample in under 15 minutes, utilizing a novel sedimentation method for bead-based immunoassays. It is compact, cost-effective, and user-friendly, requiring no sample preparation while maintaining high sensitivity and multiplexing capabilities. The technology, currently at TRL 5-6, is looking for partners for commercialization through licensing and cooperative research agreements.

1. SpinDx™
A new portable point of care
diagnostic platform to run multiple
assays in minutes from a single drop
of blood or other bodily fluids
Anup Singh, Ph.D.
Sandia National Laboratories is a multi-program laboratory managed and operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corporation, for
the U.S. Department of Energy’s National Nuclear Security Administration under contract DE-AC04-94AL85000. SAND NO. 2011-XXXXP

2. SpinDx ™ Description
A lab-on-a-disk prototype platform with the potential to run up to 64
simultaneous assays in a matter of minutes using a single drop of
blood, saliva, urine, or other sample.
Key Advantages:
1) Small size and cost (< $1000 for the
reader, <$2 for disk)
2) Analytical sensitivity (>10-100-fold better
than most commercial ELISAs)
3) Multiplexing (up to 64 assays per disk)
4) Fast (sample-to-answer in <15 min )
5) No sample prep required

3. How does it work?
 SpinDx is a “plug and play” device that
consists of a reader and a disk containing
the reagents for assays
 User needs to add 2-20L of whole blood,
serum, or saliva to the disk, load the disk
into the reader, and hit the “start” button to
run the assay
 Assay takes about 15 min and the results
are displayed on the LCD screen of the
device or on a computer connected to the
device
 Disk is single use, but can run up to 64
assays simultaneously on the same sample

4. What is the underlying technology
 SpinDx uses a novel sedimentation
approach to conduct bead-based sandwich
immunoassays.
 Disk contains fluorescently-labeled
“detection” antibodies and beads carrying
“capture” antibodies in the sample loading
chamber. Disk also contains density
centrifugation media in the separation zone.
 Sample is loaded and incubated for a few
minutes. Then disk is spun to separate the
beads from unreacted reagents and sample.
 An optical detector reads the fluorescence
signal from the sedimented beads.

5. Competitive Differentiation from other
centrifugal devices
5
www.abaxis.com
www.gyros.com
Samsung, LLC
• Our method is different -- no other
platform uses bead-based assays
together with sedimentation.
• Combination of high surface area offered
by beads, integration of signal over
multiple beads, and complete removal of
sample matrix before detection provides
unsurpassed detection sensitivity.
• No sample preparation required even for
whole blood, making SpinDx easy to use
and compatible with many types of
sample matrices.
• Assays are fast and the reader is simple
and inexpensive.

6. Key Advantages: No Sample Prep
 Density-based sedimentation allows analysis of complex sample matrices
(sample matrix is completely separated from beads before detection)
 Compatible with clinical (whole blood, serum, saliva), environmental, and food
samples

7. Key Advantages: Multiplexing
 Disk can have up to 64 channels and each channel can perform
one assay starting from a single sample. Sample is automatically
distributed among 64 channels
 Single inlet port, sample routed via capillary action
 Repeatable volume dispensing using channel geometry

8. Key Advantages: Size, Cost and Speed
 Device dimensions = 5.2” (132mm)
cubed; disk diameter ~ 4”
 Sample-to-answer time: ~15 min for
most assays; extreme sensitivity
may require additional incubation
time making the total assay time
~30 min
 Estimated cost to produce SpinDx in
large quantity
 Disks: Less than $2
 Device: less than $1000

9. Technology Opportunity
Current Technology Readiness Level (TRL): 5-6
 working prototype; have developed assays for cytokines,
cardiac markers, immune response markers and biotoxins.
Commercial readiness:
 Disks are easily manufacturable from inexpensive plastic
 Beads used are commercially available and conjugation
chemistry is simple
 Device uses standard commercially available components
Intellectual Property:
 6 U.S. patent applications pending
 Currently licensed nonexclusively to two companies

10. What are we looking for?
Partners to commercialize
technology via
 Licensing
 Currently pursuing nonexclusive
Field of Use licensing for this
technology
 CRADAS
 Currently pursuing CRADA
partners to further
commercialization efforts

11. Contact Information
For information about CRADAs or licensing this technology:
Bianca Thayer, Licensing Executive
(925)-294-1214
bkthaye@sandia.gov
To view a video about SpinDx™, go to the following website:
http://www.youtube.com/watch?v=sXMCqdFj41Q&feature=youtu.be
To access publications and articles about SpinDx™, go
to this website:
https://ip.sandia.gov/technology.do/techID=82